The Advanced Genomics Collaboration (TAGC) has awarded funding to four new Innovation Projects led by University of Melbourne researchers collaborating with partners across the Melbourne Biomedical Precinct.
Developing a rapid multi-omic liquid biopsy blood test utilising whole genome sequencing to resolve the difficult diagnosis of cancer of unknown primary origin.
Establishing a comprehensive patient dataset of inherited retinal diseases, providing information to drive new treatments and therapies for the most common cause of blindness in working-aged Australians.
Performing next-generation sequencing to find new solutions for patients with common endometrial-related health problems such as abnormal menstrual bleeding, infertility and pregnancy disorders.
A trial using genomic testing and predictive disease modelling to guide therapy and reduce the burden of prostate cancer diagnosis, which evidence suggests is over-diagnosed and over-treated in early disease.
Precision medicine allows us to develop treatments for a specific disease in one person. But we must ensure all Australians can access these benefits
TAGC was proud to sponsor the University of Melbourne’s annual MDHS Honours Conference this year, in line with the partnership’s commitment to supporting scholarship and learning opportunities to equip the next generation of researchers with the skills to lead the genomic workforce of the future.
Master of Epidemiology student Phoebe Yu wanted to learn more about the latest innovations in genomics research. An internship with Illumina gave her new experience in marketing and strengthened her analytical skills.
University of Melbourne Masters of Genomics and Health graduate Ryan O’Keeffe learned a new side to the genomics industry through a biotech internship with Illumina.
An internship at Illumina Australia gave Cathy Wu an opportunity to combine her passion for science with an interest in marketing.
The TAGC team recently received full diagnostic accreditation through the National Association of Testing Authorities (NATA) to perform ‘ctDNA profiling’ analysing tumour DNA collected via liquid biopsy. It’s a crucial step towards making advanced genomics testing more affordable and accessible.
Ethan Lang Nicholas is a Bachelor of Science student, majoring in computational biology, at The University of Melbourne. He undertook a three-month internship with Illumina's ANZ marketing team in early 2022.
The University of Melbourne and the Peter MacCallum Cancer Centre will establish a new centre to transform how genomics and precision oncology is delivered in Australia.
Caitlin Kane was a final year Bachelor of Science student, majoring in microbiology, when she undertook at two-month internship with Illumina's Asia-Pacific marketing team in early 2021.
Robiel Abraham was undertaking a Bachelor of Science, majoring in neuroscience, when he did a two-month internship with Illumina in early 2022. "This internship provided me with experience of working in a more autonomous professional environment, which was really eye opening."
Greta Medawar is a second-year Master of Biotechnology student at the University of Melbourne. She undertook a six-week internship with Illumina's ANZ marketing team, mapping out the landscape of Next-Generation Sequencing (NGS)-based cancer research in the region.
Genomics projects with a demonstrable commercial focus are invited to apply for up to $2 million in funding from The Advanced Genomics Collaboration (TAGC). To be eligible, applicants must be based at The University of Melbourne and MACH partner organisations.
Developing cancer tumours shed microscopic amounts of information into our bloodstream and deciphering these messages provides new ways to diagnose and treat it.
By combining global datasets, researchers can give more people access to genomic medicine, personalised treatment and knowledge of human DNA and disease.
Australia’s world-class medical research has transformed cancer care, but patients may not see the benefits of new genetic testing without new funding models.
Using genomic tools for detection and monitoring of circulating tumour DNA (ctDNA) in patient blood samples to enable cancer detection, surveillance and recurrence screening.
Genomics platform to understand the varied types of disease progression of patients with COVID-19, which will help to identify what treatment is best suited to individual patients.
Cancer treatment is largely based on where it originates in the body, but when a primary site can’t be found, genomics is helping guide diagnosis and treatment for cancers of unknown origin.
With the COVID-19 pandemic highlighting the importance of testing, and our capacity to undertake it at large scale, can we use these testing strategies for earlier diagnosis of cancer?
The University of Melbourne, together with international genomics company, Illumina, have welcomed the Victorian Government’s support to establish a $60 million world-leading genomics hub in Victoria.
Mapping the human genome is revolutionising medicine. The aim? To turn cancer into a manageable, chronic disease like diabetes.
.svg)
